Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3286 Target Snapshot

Urokinase-type plasminogen activator · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,731Compounds
296Assays
5Approved Drugs
1,614.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Urokinase-type plasminogen activator shows approved-linked disease relevance led by Recurrent thrombophlebitis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P00749. Start with Recurrent thrombophlebitis, then reuse UniProt P00749 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Recurrent thrombophlebitis, then reuse UniProt P00749 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Recurrent thrombophlebitis

Urokinase-type plasminogen activator shows approved-linked disease relevance led by Recurrent thrombophlebitis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Recurrent thrombophlebitis because it currently carries approved-linked support. Linked drugs include UROKINASE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Urokinase-type plasminogen activator as ChEMBL target CHEMBL3286, mapped to UniProt P00749. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Urokinase-type plasminogen activator
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3286
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00749
Urokinase-type plasminogen activator
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Urokinase-type plasminogen activator is the right protein anchor across sources, using UniProt P00749 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Recurrent thrombophlebitis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameUrokinase-type plasminogen activator
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP00749
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelUrokinase-type plasminogen activator
UniProt AccessionP00749
Component TypeProtein
Sequence Length431 aa

Urokinase-type plasminogen activator

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Urokinase-type plasminogen activator, mapped to UniProt P00749. Sequence length is 431 aa.

Mapped IDP00749
Review nameUrokinase-type plasminogen activator
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Urokinase-type plasminogen activator shows approved-linked disease relevance led by Recurrent thrombophlebitis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Recurrent thrombophlebitis
1 linked drug · 1 direct · 1 efficacy
Linked drugUROKINASE
Late clinical Phase III
empyema
1 linked drug · 1 direct · 1 efficacy
Linked drugUROKINASE
Late clinical Phase III
infection
1 linked drug · 1 direct · 1 efficacy
Linked drugUROKINASE
Late clinical Phase III
stroke
1 linked drug · 1 direct · 1 efficacy
Linked drugUROKINASE
Clinical signal Phase II
pleural empyema
1 linked drug · 1 direct · 1 efficacy
Linked drugUROKINASE
Clinical signal Phase II
pulmonary embolism
1 linked drug · 1 direct · 1 efficacy
Linked drugUROKINASE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Recurrent thrombophlebitis because it currently carries approved-linked support. Linked drugs include UROKINASE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseRecurrent thrombophlebitis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
4
Phase III
3
Phase II
Assay Mix

Activity Type Distribution

IC50528.0
KI1,074.0
KD12.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL73737 9.34 Ki 0.46 Preclinical
CHEMBL104166 9.21 IC50 0.62 Preclinical
CHEMBL104166 9.21 Ki 0.62 Preclinical
CHEMBL226714 8.85 Ki 1.4 Preclinical
CHEMBL385900 8.82 IC50 1.5 Preclinical
CHEMBL228113 8.8 Ki 1.6 Preclinical
CHEMBL562412 8.8 Ki 1.585 Preclinical
CHEMBL104505 8.7 Ki 2.0 Preclinical
CHEMBL320233 8.68 Ki 2.1 Preclinical
CHEMBL385158 8.59 IC50 2.6 Preclinical
Distribution

pChEMBL Value Distribution

194
5.0
177
5.5
187
6.0
151
6.5
109
7.0
53
7.5
48
8.0
10
8.5
4
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

296
Total Assays
1,147
Tested Compounds
3
Assay Types
Binding — 284 assays, 1,147 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 267 1,088 6.0
cell-based format 15 43 5.4
cell-free format 2 16 6.2
Functional — 7 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 7 0 —
ADME — 5 assays, 22 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 3 13 6.7
cell-based format 2 9 4.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine